Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial
一项多中心、III期、随机、双盲、等效性临床试验，旨在比较拟上市的奥马珠单抗生物类似药与原研药在治疗未控制的中重度过敏性哮喘方面的疗效和安全性。
期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1425906
Ghanei, Mostafa; Ghalebaghi, Babak; Sami, Ramin; Torabizadeh, Mehdi; Mirsadraee, Majid; Amra, Babak; Tavakol, Marzieh; Raji, Hanieh; Fallahpour, Morteza; Kiani, Arda; Abedini, Atefeh; Jabbari Azad, Farahzad; Mahdaviani, Seyed Alireza; Attaran, Davood; Samet, Mohammad; Tavana, Sasan; Haddadzadeh Shoushtari, Maryam; Nazari, Javad; AghaeiMeybodi, FatemehAlsadat; Fazlollahi, Mohammad Reza; Ghasemi, Ramin; Sabzvari, Araz; Kafi, Hamidreza; Idani, Esmaeil
